SPDR S&P Biotech ETF
473 hedge funds and large institutions have $6.29B invested in SPDR S&P Biotech ETF in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 122 increasing their positions, 157 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
7.56% less ownership
Funds ownership: 148.18% → 140.63% (-7.6%)
22% less repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 157
72% less call options, than puts
Call options by funds: $882M | Put options by funds: $3.12B
Holders
473
Holding in Top 10
11
Calls
$882M
Puts
$3.12B
Top Buyers
| 1 | +$454M | |
| 2 | +$367M | |
| 3 | +$187M | |
| 4 |
Wells Fargo
San Francisco,
California
|
+$122M |
| 5 |
Barclays
London,
United Kingdom
|
+$78.9M |
Top Sellers
| 1 | -$1,000M | |
| 2 | -$620M | |
| 3 | -$185M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$69.9M |
| 5 |
DA
Duality Advisers
Miami,
Florida
|
-$67.2M |